|
Synonyms: MM-121 | SAR256212
Compound class:
Antibody
Comment: Seribantumab is a fully humanised IgG2 monoclonal antibody targeting ERBB3 (HER3) [1].
Peptide sequences for this antibody are available from its IMGT/mAb-DB record. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| Seribantumab is being investigated in Phase 2 clinical trials for the treatment of various types of solid tumours including non-small cell lung cancer (NSCLC), breast cancer, epithelial ovarian cancer, fallopian tube cancer and peritoneal cancer. Seribantumab is being compared with, or in combination with, other anti-cancer drugs such as erlotinib, exemestane, irinotecan, cetuximab and paclitaxel. |
| Mechanism Of Action and Pharmacodynamic Effects |
| Modelling of the ErbB signalilng network has identified ERBB3 as a key node in the activation of the ErbB-phosphatidylinositol 3-kinase (PI3K) axis [1]. This model is verified in vitro by blocking ERRB3-induced activation of AKT with the ERBB3 specific monoclonal antibody, seribantumab (MM-121). In vivo, this antibody inhibits tumour growth in mouse xenograft models [1]. Heregulin -1β (HRG1-β) signalling to AKT is predicted to occur primarily via ERBB3/ERBB2 heterodimers. |
